Compare Prudential Financial Inc (PRU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs GeneDx Holdings Corp — how do they compare? Prudential Financial Inc trades at $113.09 (market cap $39.17B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Prudential Financial Inc is far larger — about 19.4× GeneDx Holdings Corp's market cap, and Prudential Financial Inc pays a 4.93% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and GeneDx Holdings Corp for 19 Days on average.
| PRU | WGS | |
|---|---|---|
Market Cap | $39.17B | $2.02B |
Volume | 1,436,917 | 734,640 |
Sector | Financials | Health |
52-Week High | $125.13 | $167.51 |
52-Week Low | $92.00 | $34.51 |
Typical Hold Time | 145 Days | 19 Days |
Enterprise Value | $67.95B | $2.05B |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.53, up 1.04% with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.29 and P/S of 0.61, while maintaining solid profitability with 6.04% net margin and 12.46% ROE. Recent developments include strategic partnerships, the Alexforbes stake sale, and rebranding to Prudential Wealth Advisors, reflecting ongoing business transformation.
PRU presents a mixed outlook with strong fundamentals offset by technical weakness. The company's $3 billion capital rotation plan and focus on core businesses provide growth potential, but investor sentiment remains cautious with 67.57% hold ratings. Key risks include execution of strategic initiatives and interest rate sensitivity, while current valuation below consensus target offers potential upside for patient investors.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
